Abstract
abstract The article encompasses the present and future pharmacotherapies involved in managing type 2 diabetes (T2D). It is divided into three sections: recent treatment modalities of the last decade, upcoming approved drugs to be available in India, and near future drugs under clinical trials. It highlights the oral hyperglycaemic agents and insulin options available in India, their potential effects on diabetes outcomes and the clinical trials. India is a fast and dynamic adopter of novel treatments and newer technologies with off-patent and in-patent modalities. Medicinal novelties surround T2D, but technological advancements have touched newer heights with surreal support of artificial intelligence-based innovations, especially in type 1 diabetes management.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
